BDSX (Biodesix) Insider Ownership: 35.55 % (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDSX Biodesix Inc BDSX
51 GF Score
Price $26.87
GF Value $21.13
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Biodesix Insider Ownership?

Biodesix BDSX +1.68% 51 Insider Ownership is 35.55 % as of Sep. 09, 2026. GuruFocus rates BDSX with a GF Score™ of 51/100 and a GF Value™ of $21.13 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biodesix's insider ownership is 35.55%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biodesix's Institutional Ownership is 41.41%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biodesix's Float Percentage Of Total Shares Outstanding is 57.76%.

Biodesix Insider Ownership Historical Data

* Premium members only.

The historical data trend for Biodesix's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biodesix Insider Ownership Chart

Biodesix Historical Data

The historical data trend for Biodesix can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Insider Ownership 3.64 72.86 67.60 46.85 46.90 45.42 36.21 36.21 36.22 35.55
BDSX
51GF Score
Biodesix Inc BDSX
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biodesix Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 35.55 % mean?
Biodesix (BDSX) has a Insider Ownership of 35.55 % as of Sep. 09, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Biodesix and its competitors.
Is Biodesix's Insider Ownership too high?
Biodesix's current Insider Ownership is 35.55 %. Overall, Biodesix has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biodesix's Insider Ownership compare to MYGN and XGN?
Biodesix's Insider Ownership of 35.55 % can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Medical Diagnostics & Research company?
A good Insider Ownership depends on the Medical Diagnostics & Research industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Biodesix and its competitors. Biodesix's current Insider Ownership is 35.55 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biodesix stock overvalued right now?
Based on GuruFocus' analysis, Biodesix (BDSX) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.13, compared to a current price of $26.87 — trading 27.2% above its estimated fair value. The current Insider Ownership is 35.55 %. Biodesix's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Biodesix (BDSX), the current Insider Ownership is 35.55 % as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biodesix (BDSX) Overvalued in 2026?

Based on GuruFocus' analysis, Biodesix stock appears to be overvalued. The current stock price of $26.87 is trading 27.2% above its estimated GF Value™ of $21.13. GuruFocus considers Biodesix to be Modestly Overvalued.

Key valuation signals for BDSX:

  • Insider Ownership: 35.55 %
  • GF Value™: $21.13 vs. price of $26.87 (27.2% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the BDSX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biodesix Business Description

Address 919 West Dillon Road, Louisville, CO, USA, 80027
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
51GF Score

Get the complete analysis for BDSX

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.87
Price
$21.13
GF Value